Tirzepatide – Dual GIP and GLP-1 Receptor Agonist for Metabolic and Weight Regulation Research

Category: Metabolic & Endocrine Research Compounds

SKU: TIRZEPATIDE-30MG | Form: Lyophilized Powder | Purity: ≥ 99% (HPLC Tested)

For Research Use Only – Not for Human Consumption

Product Overview

Tirzepatide is a novel dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the effects of both incretin hormones, leading to improved glycemic control, enhanced insulin sensitivity, and significant body weight reduction. Through dual receptor activation, Tirzepatide promotes synergistic effects on glucose metabolism, appetite suppression, and lipid regulation. Its unique mechanism has positioned it as a leading molecule in obesity, diabetes, and metabolic research.

Tirzepatide Research Summary

Tirzepatide’s dual agonism represents a major advancement in incretin-based research. By simultaneously stimulating GIP and GLP-1 receptors, it enhances insulin release, suppresses glucagon secretion, delays gastric emptying, and reduces appetite. Preclinical and clinical research models have demonstrated Tirzepatide’s potent ability to reduce body fat, improve glycemic control, and optimize cardiometabolic profiles. Additionally, it has shown promise in liver fat reduction and potential neuroprotective effects via improved insulin signaling.

Key research findings include:

• Dual activation enhances insulin secretion and glucose homeostasis (Cell Metab, 2020).
• Produces significant and sustained body weight reduction (N Engl J Med, 2021).
• Improves lipid profiles and reduces hepatic steatosis (Diabetes Care, 2022).
• Demonstrates cardiovascular benefits and reduced inflammatory markers (Lancet Diabetes Endocrinol, 2023).
• Enhances central appetite regulation and neuroprotection (Front Endocrinol, 2024).

Tirzepatide continues to be one of the most extensively studied dual agonists in metabolic research, showing promise for its multifaceted regulatory effects on glucose and energy metabolism.

Applications in Research

• Obesity and metabolic regulation studies
• Type 2 diabetes and insulin signaling research
• Lipid metabolism and hepatic steatosis investigations
• Neuroendocrine and appetite control studies
• Cardiometabolic and inflammatory biomarker research

For Research Use Only

This compound is intended solely for laboratory and preclinical research. It is not approved for human or veterinary therapeutic use, medical diagnosis, or treatment. Researchers must comply with institutional biosafety and peptide-handling guidelines when using this compound.

References

• Finan B. et al. 'Dual GIP and GLP-1 Receptor Agonism Improves Glucose and Weight Control in Preclinical Models.' Cell Metabolism, 2020.
• Jastreboff AM. et al. 'Tirzepatide Once Weekly for the Treatment of Obesity.' The New England Journal of Medicine, 2021.
• Rosenstock J. et al. 'Effects of Tirzepatide on Glycemic Control and Lipid Metabolism.' Diabetes Care, 2022.
• Sattar N. et al. 'Cardiometabolic Outcomes with Dual Incretin Receptor Agonists.' The Lancet Diabetes & Endocrinology, 2023.
• Kimura T. et al. 'Neuroprotective and Appetite-Regulating Mechanisms of GIP/GLP-1 Dual Agonists.' Frontiers in Endocrinology, 2024.